另外，华检医疗近日公布，旗下一间全资附属公司华检科技已于香港注册成立。该公司拟主要从事人工智能(AI)相关项目。公司认为，于集团营运中采用AI，能够提升集团的体外诊断(IVD)产品开发工作。IVD medical (01931) rose more than 20%, as of the time of writing, up 20.93%, reported HKD 1.04, with a turnover of HKD 3.7177 million.
According to the smart finance and economics APP, IVD medical (01931) rose more than 20%, as of the time of writing, up 20.93%, reported HKD 1.04, with a turnover of HKD 3.7177 million.
On the news front, IVD Medical released its interim performance for the six months ending June 30, 2024, with a group income of RMB 1.353 billion, a 1.7% year-on-year decrease; shareholders' attributable profit of RMB 0.125 billion, a 21.6% year-on-year increase; earnings per share of 9.27 cents. The announcement stated that the increase was mainly due to the rise in the gross margin of the group's after-sales service business.
In addition, IVD Medical recently announced the establishment of its wholly-owned subsidiary, Huajian Technology, in Hong Kong. The company plans to engage primarily in projects related to artificial intelligence (AI). The company believes that the use of AI in the group's operations can enhance the development of the group's in vitro diagnostics (IVD) products.